Event

OSCO Presents Best of ASCO

The Oklahoma Society of Clinical Oncology, Inc.

The Oklahoma Society of Clinical Oncology, Inc. would like to invite you to attend our 2025 In-Person Fall Conference, which will be an officially licensed BEST OF ASCO event held at Andrews Academic Tower on Saturday, September 27th.  his conference will highlight the foremost research and strategies in oncology that were presented by speakers at the 2025 American Society of Clinical Oncology’s (ASCO®) Annual Meeting. This conference is designed to update the educational needs of Hematologists/Oncologists, Nurses, Pharmacists, Physician Assistants, and other healthcare professionals specializing in oncology.  This activity will be approved for continuing education credits for physicians, pharmacists, and nurses. There is no fee for this conference, but registration is required.

This activity will be approved for 4 hours of continuing education credits for physicians, nurses, and pharmacists.  There is no fee for this conference, but registration is required.

BEST OF ASCO® is an officially licensed program of the American Society of Clinical Oncology, Inc. (ASCO®).

This conference is jointly provided by the Postgraduate Institute for Medicine and the Oklahoma Society of Clinical Oncology, Inc.

  • For more information contact OSCO Executive Director Kathleen Musson by e-mail to kmusson@nextwavegroup.net
  • For Corporate Member registration, please contact Kathleen directly at the email above.
  • All trainees to participate in our Trainee Research Abstract competition which will be conducted on September 27th, 2025, at the Andrews Academic Tower, Oklahoma City, OK.  Click here to find out more about the competition.

Online Registration is now closed.  Please come to the event and register on site.

Show Agenda
  • 7:00 am
    Exhibitor Set up
  • 7:30 am
    Registration & Continental Breakfast Opens
  • 8:00 - 8:15 am
    Welcome Remarks – Adanma Ayanambakkam, MD, OSCO President Elect
  • 8:15 am – 9:00 am
    Updates in Gastrointestinal Oncology
    Elad Sharon, MD, MPH

    Elad Sharon, MD, MPH

    Updates in Gastrointestinal Oncology

    Clinical and Translational Director of the Immunotherapy Toxicity Program Dana-Farber Cancer Institute, Faculty, Harvard Medical School, Boston, MA

  • 9:15 am – 10:15 am
    Updates in Myeloma
    Jens Hillengass, MD, PhD

    Jens Hillengass, MD, PhD

    Updates in Myeloma

    Chief of Myeloma and Professor of Oncology, Roswell Park Cancer Institute, Buffalo, New York

  • 10:15–10:45 AM
    Break for exhibits/refreshments, view abstracts
  • 10:45 am – 11:00 am
    Oral Presentation by Resident Abstract Winner
  • 11:00 am – 12:00 pm
    Updates in GU Oncology
    Tian Zhang, MD, MHS, FASCO

    Tian Zhang, MD, MHS, FASCO

    Updates in GU Oncology

    Associate Director for Clinical Research , Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX

  • 12:00 -1:00 PM
    Updates in Thoracic Oncology
    Abdul Rafeh Naqash, MD

    Abdul Rafeh Naqash, MD

    Updates in Thoracic Oncology

    OU Health Stephenson Cancer Center — Oklahoma TSET Phase I Program

  • 1:00 PM
    Announcement of Resident Abstract Award Winners
  • 1:15 pm
    Adjournment